These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10070137)

  • 21. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension.
    Callera GE; Touyz RM; Teixeira SA; Muscara MN; Carvalho MH; Fortes ZB; Nigro D; Schiffrin EL; Tostes RC
    Hypertension; 2003 Oct; 42(4):811-7. PubMed ID: 12913063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure and small arteries in DOCA-salt-treated genetically AVP-deficient rats: role of endothelin.
    Intengan HD; Park JB; Schiffrin EL
    Hypertension; 1999 Oct; 34(4 Pt 2):907-13. PubMed ID: 10523383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of the endothelin ET(B) receptor in gender differences in deoxycorticosterone acetate-salt-induced hypertension.
    Kawanishi H; Hasegawa Y; Nakano D; Ohkita M; Takaoka M; Ohno Y; Matsumura Y
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):280-5. PubMed ID: 17324138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan.
    Larivière R; Sventek P; Thibault G; Schiffrin EL
    Can J Physiol Pharmacol; 1995 Mar; 73(3):390-8. PubMed ID: 7544236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of magnesium on mRNA expression and production of endothelin-1 in DOCA-salt hypertensive rats.
    Berthon N; Laurant P; Fellmann D; Berthelot A
    J Cardiovasc Pharmacol; 2003 Jul; 42(1):24-31. PubMed ID: 12827022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats.
    Hoagland KM; Flasch AK; Roman RJ
    Hypertension; 2003 Oct; 42(4):669-73. PubMed ID: 12874093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats.
    Viel EC; Benkirane K; Javeshghani D; Touyz RM; Schiffrin EL
    Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H281-8. PubMed ID: 18487445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy.
    Li JS; Larivière R; Schiffrin EL
    Hypertension; 1994 Aug; 24(2):183-8. PubMed ID: 8039842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension.
    Li L; Watts SW; Banes AK; Galligan JJ; Fink GD; Chen AF
    Hypertension; 2003 Sep; 42(3):316-21. PubMed ID: 12885792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats.
    Callera GE; Montezano AC; Touyz RM; Zorn TM; Carvalho MH; Fortes ZB; Nigro D; Schiffrin EL; Tostes RC
    Hypertension; 2004 Apr; 43(4):872-9. PubMed ID: 14993193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension.
    Li L; Fink GD; Watts SW; Northcott CA; Galligan JJ; Pagano PJ; Chen AF
    Circulation; 2003 Feb; 107(7):1053-8. PubMed ID: 12600921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ETA receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats.
    Fujita K; Matsumura Y; Miyazaki Y; Hashimoto N; Takaoka M; Morimoto S
    Life Sci; 1996; 58(1):PL1-7. PubMed ID: 8628104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms.
    Callera GE; Tostes RC; Yogi A; Montezano AC; Touyz RM
    Clin Sci (Lond); 2006 Feb; 110(2):243-53. PubMed ID: 16271043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced NO production rapidly aggravates renal function through the NF-κB/ET-1/ETA receptor pathway in DOCA-salt-induced hypertensive rats.
    Kimura K; Ohkita M; Koyama M; Matsumura Y
    Life Sci; 2012 Oct; 91(13-14):644-50. PubMed ID: 22569294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats.
    Fareh J; Touyz RM; Schiffrin EL; Thibault G
    Hypertension; 1997 Nov; 30(5):1253-9. PubMed ID: 9369284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
    Arai K; Morikawa Y; Ubukata N; Tsuruoka H; Homma T
    J Pharmacol Exp Ther; 2016 Sep; 358(3):548-57. PubMed ID: 27384074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of endothelin B receptors in kidneys of DOCA-salt hypertensive rats.
    Pollock DM; Allcock GH; Krishnan A; Dayton BD; Pollock JS
    Am J Physiol Renal Physiol; 2000 Feb; 278(2):F279-86. PubMed ID: 10662732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the endothelin ETA-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats.
    Fujita K; Matsumura Y; Miyazaki Y; Takaoka M; Morimoto S
    Jpn J Pharmacol; 1996 Apr; 70(4):313-9. PubMed ID: 8774759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin-A receptor blockade prevents left ventricular hypertrophy and dysfunction in salt-sensitive experimental hypertension.
    Rothermund L; Vetter R; Dieterich M; Kossmehl P; Gögebakan O; Yagil C; Yagil Y; Kreutz R
    Circulation; 2002 Oct; 106(18):2305-8. PubMed ID: 12403658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renoprotective effects of a combined endothelin type A/type B receptor antagonist in experimental malignant hypertension.
    Kohno M; Yokokawa K; Yasunari K; Kano H; Minami M; Ueda M; Tatsumi Y; Yoshikawa J
    Metabolism; 1997 Sep; 46(9):1032-8. PubMed ID: 9284892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.